• editor@pphm.life
  • Evidence. Experts. Context.
Health news, backed by evidence.
PP Health Malaysia Banner (PPHM)

ACOG Expands Menopause Guidance, Endorsing Hormone Therapy and Non-Hormonal Options for Hot Flushes and Sleep Problems

Key Insights ▼

The American College of Obstetricians and Gynecologists has issued expanded guidance on the treatment of menopause symptoms, placing hormone therapy at the centre of care for eligible people experiencing hot flushes, night sweats and related sleep disruption.

The recommendations also set out non-hormonal medicines and psychological and lifestyle-based approaches for people who cannot, or do not wish to, use hormone therapy.

The guidance is among the most comprehensive statements from the organisation on menopause management to date. It addresses vasomotor symptoms, sleep problems and mood changes, while stressing that treatment should be tailored to each person through shared decision-making.

Menopause symptoms can be substantial. According to the guidance, between 50% and 92% of people experiencing menopause report vasomotor symptoms, commonly known as hot flushes and night sweats.

Sleep difficulties are also widespread, affecting an estimated 16% to 66% of females during menopause. More than one-third of people in perimenopause or postmenopause report depressive symptoms.

The new recommendations arrive as clinicians and patients continue to navigate conflicting messages about menopausal hormone therapy, often referred to as MHT. Concerns about breast cancer, cardiovascular disease and blood clots have led some people to avoid treatment. Some clinicians have also remained cautious about prescribing it.

The updated guidance seeks to support a more individualised approach. Rather than treating hormone therapy as universally safe or universally dangerous, it encourages clinicians to assess the person’s symptoms, age, medical history and baseline health risks. Treatment goals matter too.

For eligible people with bothersome vasomotor symptoms, the ACOG strongly recommends hormone therapy containing oestrogen and a progestogen. People who have had a hysterectomy and do not have a uterus may generally use oestrogen alone, because a progestogen is not needed to protect the lining of the womb.

The organisation also conditionally recommends conjugated oestrogen combined with bazedoxifene, sold under the brand name Duavee, as an alternative option for managing hot flushes, night sweats and related sleep disturbances.

Evidence reviewed for the guidance indicates that oestrogen therapy, either alone or combined with a progestogen, can reduce the frequency and severity of vasomotor symptoms more effectively than a placebo or no treatment. A 2021 meta-analysis cited in the recommendations found a significant improvement in both measures.

The form of treatment may also affect outcomes. A 2017 meta-analysis ranked transdermal oestradiol, delivered through the skin, alongside a progestogen as one of the most effective combinations for reducing the frequency of vasomotor symptoms. Transdermal treatment includes patches, gels and sprays.

Another systematic review and meta-analysis, published in 2022, associated MHT with improved self-reported sleep quality. Transdermal therapies again produced some of the strongest effects. Sleep may improve when night sweats become less frequent, although hormone therapy could also influence sleep more directly in some people.

The ACOG recommends considering MHT before the age of 60 or within 10 years of the onset of natural menopause, when appropriate. This timing is not a blanket rule. Starting treatment still requires an assessment of individual benefits and risks.

Clinicians are advised to consider age, personal and family medical history, cardiovascular risk, breast cancer risk and the possibility of venous thromboembolism, commonly known as VTE. Treatment priorities should be discussed openly. One person may place greatest importance on controlling severe night sweats. Another may be more concerned about sleep, sexual health or the impact of symptoms on work.

There is no single menopause experience. Symptoms can be occasional and manageable, or persistent enough to affect concentration, relationships, employment and overall quality of life. The guidance therefore supports shared decision-making, where the clinician explains the available evidence and the patient takes an active role in choosing whether to begin treatment.

The recommendations are more cautious regarding depression. The ACOG states that current evidence is insufficient to recommend for or against oestrogen-progestogen therapy or oestrogen-only therapy specifically for menopause-related depressive symptoms.

People who meet diagnostic criteria for major depressive disorder should receive care based on established depression guidelines. This also applies when depression is the most prominent symptom. Menopause-related mood changes can overlap with clinical depression, but they are not interchangeable. Persistent low mood, loss of interest, feelings of hopelessness, major changes in appetite or sleep, and thoughts of self-harm require prompt medical attention.

For people who cannot use hormone therapy, or who prefer not to use it, the guidance strongly recommends several non-hormonal medicines for vasomotor symptoms and related sleep disturbance.

These include selective serotonin reuptake inhibitors, known as SSRIs, and serotonin and norepinephrine reuptake inhibitors, or SNRIs. These medicines are commonly used to treat depression and anxiety, but some can reduce hot flushes even when a person does not have a diagnosed mood disorder.

The ACOG also strongly recommends neurokinin receptor antagonists. These medicines target brain pathways involved in temperature regulation, an important mechanism behind hot flushes.

Fezolinetant, marketed as Veoza in some markets, was approved by the United States Food and Drug Administration in 2023 for the management of hot flushes. In 2025, the FDA approved elinzanetant, marketed as Lynkuet, for moderate to severe vasomotor symptoms caused by menopause. These medicines do not contain hormones, although they are not suitable for everyone and require appropriate clinical assessment.

The guidance conditionally recommends gabapentin as another non-hormonal option. Gabapentin is already used for conditions such as nerve pain and seizures. It can reduce vasomotor symptoms for some people, but possible adverse effects include drowsiness, dizziness and problems with coordination. These effects may be particularly important for older adults or people taking other sedating medicines.

Medication is only one part of the updated recommendations. The ACOG conditionally recommends cognitive behavioural therapy, mindfulness-based interventions, regular exercise, clinical hypnosis and acupuncture for vasomotor symptoms, sleep disturbance related to those symptoms and mood changes.

Cognitive behavioural therapy can help people identify unhelpful thought patterns, manage distress and develop practical strategies for coping with symptoms. It may be especially useful when hot flushes are accompanied by anxiety, insomnia or concerns about loss of control.

Mindfulness-based interventions may help people respond to symptoms with less distress. They are not expected to eliminate hot flushes completely, yet some people may find them useful for improving sleep, emotional regulation and quality of life.

Regular physical activity offers broader health benefits, including support for cardiovascular health, bone strength, muscle function and mood. Exercise should be selected according to a person’s ability and health status. Although it may not stop hot flushes in every case, it can form part of a wider menopause management plan.

Clinical hypnosis is another option included in the guidance. Some research suggests that it may reduce the burden of hot flushes for certain people, particularly when symptoms interfere with sleep or daily activities. Acupuncture has also been conditionally recommended, although results across studies have varied.

These non-pharmacological approaches are generally most useful when incorporated alongside medication, rather than presented as a replacement in every situation. People with severe symptoms may need a combination of strategies.

The ACOG does not recommend relying on phytoestrogens or herbal supplements because there is not enough evidence to establish their effectiveness or safety. Products containing soy isoflavones and other plant-derived compounds are widely promoted for menopause, but supplements are not regulated in the same way as prescription medicines. Their purity, strength and contents can vary.

Natural does not automatically mean safe. Supplements may interact with prescription medicines, affect liver function or contain ingredients that are not clearly listed on the label. Anyone considering such products should discuss them with a qualified healthcare professional.

The updated guidance also has a wider message. Menopause care should not be limited to telling people to tolerate symptoms as a normal part of ageing. Menopause is a biological transition, yet its symptoms can have serious effects on health, work and personal life.

At the same time, hormone therapy should not be presented as risk-free. Its suitability depends on the individual. A careful review of medical history is essential, particularly for people with a history of certain cancers, unexplained vaginal bleeding, blood clots, stroke, heart disease or liver disease.

The route of administration may also be relevant. Transdermal oestrogen can have a different effect on clotting risk from oral treatment, although decisions must still be made on an individual basis. The type and dose of progestogen may matter as well. These issues require clinical discussion rather than self-treatment.

Experts involved say that better information could help reduce both overuse and underuse of treatment. Some people who could benefit from hormone therapy may avoid it because of outdated or overly broad fears. Others may assume that a product is safe simply because it is marketed as natural.

The central principle is proportionate, informed care. A person with mild, occasional symptoms may choose lifestyle measures or no treatment. Someone with frequent night sweats, severe insomnia or debilitating hot flushes may reasonably consider hormone therapy or a non-hormonal medicine. Both decisions can be appropriate.

The guidance does not remove the need for professional advice. It provides a framework for conversations between patients and clinicians. Those conversations should cover symptom severity, treatment options, expected benefits, possible harms, alternatives and follow-up.

Menopause care is becoming more visible in public health discussions, workplaces and primary care. The ACOG recommendations reflect that shift, offering a broader menu of evidence-based options than many patients have previously been given.

For people struggling with symptoms, the practical message is straightforward, help is available, and treatment does not have to follow a single path. A GP, gynaecologist or other qualified clinician can assess symptoms, identify conditions that may require separate treatment and help determine which approach best fits the person’s health, preferences and priorities.

The most suitable plan may change over time. Symptoms can evolve, medical circumstances can change, and treatment can be adjusted. What matters is that menopause care remains personal, evidence-informed and open to review.

Disclaimer: Editorial content on this site is for general information only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider with any questions about your health. While we take care to ensure accuracy, we make no guarantees and accept no responsibility for any errors, omissions, outdated information or any consequences arising from use of this site. Views expressed in articles, interviews and features are those of the authors or contributors and do not  necessarily reflect the views of the publisher. References to, or advertisements for, products or services do not constitute endorsements, and we do not guarantee their quality, safety or effectiveness. You can read our editorial policy.